Transportation Studies Sample Clauses

Transportation Studies. The CONSULTANT may be required to perform on a number of multi-modal transportation studies. The studies may encompass any one of the following subject areas: travel demand modeling (multi-modal), transportation systems management, congestion management, intermodal facilities, park and ride lot planning, multi-modal alternatives analysis, transit planning, bicycle and pedestrian planning, and others. Typically, the reports would include a data collection effort, data analysis, development of alternatives and recommendations. Each work order will be developed with a scope of services detailing the efforts to be performed. A description of typical efforts may include, but shall not be limited to, the following: Data Collection - Boarding and Alighting Surveys Traffic Counts Bike/Ped Counts Classification Counts Transit Infrastructure Inventories Transit Ridership Park and Ride Lot Utilization Counts Park and Ride Lot Facilities Inventories Origin/Destination Surveys Freight Monitoring Land Use Data Employment Data Literature and/or Technology Research Mapping Sidewalk/Bicycle Lane Inventories Rail Freight Operations Data Data Analysis - Traffic Engineering Analysis Mode Split Analysis Long Range Transportation Modeling Congestion Management Studies Intermodal Feasibility Studies Transportation System Management Analysis Signal Synchronization (Systems) Preemption/Prioritization Reversible Lanes HOV Lanes Transportation Demand Management Analysis Transit Carpool Vanpool Park and Ride Lot Planning Emergency Ride Home Accident Analyses Sketch Planning Freight Mobility GIS/Database Development Bicycle/Pedestrian Planning
AutoNDA by SimpleDocs

Related to Transportation Studies

  • Transporting Students Teachers shall not be required to transport a student in a private vehicle on behalf of the school.

  • Trials The Ship shall run the following test and trials:

  • Studies The clinical, pre-clinical and other studies and tests conducted by or on behalf of or sponsored by the Company or its subsidiaries that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus were and, if still pending, are being conducted in accordance in all material respects with all statutes, laws, rules and regulations, as applicable (including, without limitation, those administered by the FDA or by any foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA). The descriptions of the results of such studies and tests that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus are accurate and complete in all material respects and fairly present the published data derived from such studies and tests, and each of the Company and its subsidiaries has no knowledge of other studies or tests the results of which are materially inconsistent with or otherwise call into question the results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, neither the Company nor its subsidiaries has received any notices or other correspondence from the FDA or any other foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA with respect to any ongoing clinical or pre-clinical studies or tests requiring the termination or suspension of such studies or tests. For the avoidance of doubt, the Company makes no representation or warranty that the results of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company will be sufficient to obtain governmental approval from the FDA or any foreign, state or local governmental body exercising comparable authority.

  • Transportation Transportation expenses include, but are not limited to, airplane, train, bus, taxi fares, rental cars, parking, mileage reimbursement, and tolls that are reasonably and necessarily incurred as a result of conducting State business. Each State agency shall determine the necessity for travel, and the mode of travel to be reimbursed.

  • Air Transportation In accordance with the standard provision entitled International Air Transportation, any international travel requires prior written approval from the FHI360 contracts administrator.

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Clinical 2.1 Provides comprehensive evidence based nursing care to patients including assessment, intervention and evaluation.

  • Public Transportation Taxi or airport limousine services may be considered when traveling in and around cities or to and from airports when less expensive means of transportation are unavailable or impractical. The actual fare plus a reasonable tip (15-18%) are reimbursable. In the case of a free hotel shuttle to the airport, tips are included in the per diem rates and will not be reimbursed separately.

  • Groundwater The groundwater shall not be degraded as a result of the waste maintained at the facility.

Time is Money Join Law Insider Premium to draft better contracts faster.